Non-alcoholic Steatohepatitis Clinical Trials Market Size, Estimates, And Forecast To 2030
Non-alcoholic Steatohepatitis Clinical Trials Market Growth & Trends The global non-alcoholic steatohepatitis clinical trials market size is expected to reach USD 4.2 billion by 2030, registering a CAGR of 6.5% over the forecast period, according to a new report by Grand View Research, Inc. Rising healthcare expenditure, cases of obesity, and prevalence of non-alcoholic steatohepatitis (NASH) are the factors driving the growth of this market. Due to the COVID-19 pandemic, enrollment in new drug clinical trials for NASH patients was halted, but people shifted to alternate means of data collecting methods, like virtual visits. Non-alcoholic Steatohepatitis is a fatty liver disease that causes scarring and damage to the liver. Non-alcoholic Steatohepatitis Clinical Trials Market Segmentation Grand View Research has segmented the global non-alcoholic steatohepatitis clinical trials market based on phase, study design, and region: Based on the Phase I...